Leadership

John Alberico

President and Chief Executive Officer

John was the Managing Director of Inverness Medical Limited (“Inverness”) subsidiary in Scotland which manufactured the company’s glucose testing strips. During his 21-month tenure, he spearheaded efforts to increase the operation’s efficiency, building the capacity to cost-effectively produce over 1 billion test strips annually. He was also responsible for the transfer of the manufacturing of the company’s meter products to China.

Prior to Inverness, John was the Vice President of Operations for Bionostics Inc., a medical reagents and controls company, and the Vice President of Manufacturing for Nova Biomedical, a medical instrumentation company. John is also the founder of Medical Devices, Inc., an engineering consulting company specializing in the offshore contract manufacturing of high volume consumer medical devices. He holds a B.S. in Biomedical Engineering from Boston University.

Jackson McAdam

Chief Financial Officer

Since joining AgaMatrix in 2014, Jackson McAdam has steadily moved from his initial Director’s role to the Company’s most senior financial professional. A key participant in the Company’s recent strategic efforts, Jackson was integral in the acquisition of the CGM platform from iSense CGM, Inc. and Bayer Healthcare in early 2016 as well as the financing and tax reorganization efforts leading to the recent Prospect Capital deal for $32-million.

Prior to joining AgaMatrix, Jackson spent a total of nine years with Kronos Incorporated, a private equity owned software and service organization reporting $1 billion in annual revenues where he held various senior finance positions. Jackson also served as Director of Internal Audit with a supply chain management services company, Moduslink Global for three years and began his career with PricewatershouseCoopers. He holds a B.S. in Accounting from Bentley College.

Chuck Johnson

Vice President of Engineering

A veteran technical manager, Chuck joined AgaMatrix in 2011 and has since held a senior leadership role for the Company’s engineering development activities. Chuck has been a key contributor to the Company’s product portfolio from the first FDA-cleared blood glucose monitor to connect directly to the iPhone, iBGStar to our latest Jazz Wireless 2 meter. Chuck’s nearly 40 years of engineering experience has involved a number of successful roles in the medical device industry including the Director of Engineering at Eleme Medical (acquired by Cynosure) overseeing the development of systems to treat kidney stones, vascular lesions, wrinkles, cellulite, tattoo removal and removal of unwanted hair, and Vice President, Development Engineering at Candela Corporation where he was responsible for the development of the company’s variable pulse duration YAG Laser for hair removal which was the company’s most successful product.

Chuck earned his Master’s degree in Electrical Engineering from Worcester Polytechnic Institute and his Bachelor’s in Electrical Engineering from Manhattan College.

David Olsen

Vice President, Quality Assurance, Regulatory and Clinical Affairs

Mr. Olsen joins AgaMatrix with 25 years of experience as a Regulatory Affairs & Quality professional in the IVD, Medical Devices, Biotechnology and Biologics environment. His extensive experience in new product development and licensure within the U.S., Canada, European Union, Brazil, India and China includes his most recent role at Harvard Apparatus Regenerative Technology, Inc., a Holliston, MA biotechnology company specializing in the development of cell based tracheal prostatic where he worked as Director of Regulatory Affairs, Clinical Affairs and Quality Assurance. Among his previous roles David served as Vice President, Corporate Regulatory & Quality for 5 years at SeraCare Life Sciences, Inc., a $60M IVD Biotechnology Company specializing in the manufacture of serological and nucleic acid controls and reference materials. Dave has also held executive and management positions with Defibtech, LLC, American Red Cross, and C.R. Bard, Inc. David earned his JD from the Massachusetts School of Law, his BS in Chemistry from Salem State University, and an LL.M. in Banking and Financial Law at Boston University School of Law.

Cara Mottolo

Vice President of Human Resources

Cara has lead the organization’s Human Resources efforts since joining AgaMatrix late in 2010 and oversees all personnel activities for the Companies’ more than four hundred employees located in the United States, Hong Kong, China and the United Kingdom. A key participant in the Company’s acquisitions, Cara has guided the personnel integration in 2014 of the meter factory in Dongguan, China as well as the 2016 CGM entity in Wilsonville, Oregon. Cara also serves as the the main point of contact for the Company’s shareholders and employees regarding equity administration.

During Cara’s seventeen years in the Human Resources profession, she has lead efforts in a variety of industries from the medical device company NMT Medical, Inc. to the sports and entertainment venue the Boston Garden (at the time the FleetCenter). Much earlier in her professional career, Cara spent time in Broadcast Journalism with on air positions at several local radio stations. She holds a B.A. in Communications from the University of Massachusetts, Amherst.

Lewis Capriccio

Director of Operations

Lew joined AgaMatrix in 2005 and has served in both engineering and management roles. He has over 30 years experience in product development and manufacturing.

Prior to AgaMatrix, he worked for BioValve Technologies, Inc., an R&D company, designing and implementing the pilot manufacturing line for a controlled release disposable insulin pump. He served as the Mechanical Engineering Manager at Cytyc Corp. (Hologic), designing and managing the development of automated clinical test equipment for woman’s healthcare. He was Sr. Mechanical Engineer at Nova Biomedical, a medical instrumentation company. Prior to his work in the medical equipment field, Lew worked for GCA Corp., designing and manufacturing high precision semiconductor wafer fabrication equipment. He earned his B.S. in Mechanical Engineering from Northeastern University.

David Olson, Ph.D

Director of Scientific Development

David Olson joined AgaMatrix in 2014 with 10+ years of experience in biosensor research and development. Prior to AgaMatrix, he led the sensor engineering group at Echo Therapeutics in the development of a non-invasive, transdermal continuous glucose monitor, focusing on improving manufacturing and performance repeatability as well as constructing the measurement algorithm. Prior to that, he was a Principal Scientist in a San Francisco Bay Area consulting firm that provided technical expertise in biosensor development and manufacturing to companies ranging from early startups to established players, such as Roche and Bayer.

Dave earned his B.S. in chemical engineering from Northwestern University and his Ph.D. in chemical engineering from Stanford University.

John Alberico

Director, President and Chief Executive Officer

John was the Managing Director of Inverness Medical Limited (“Inverness”) subsidiary in Scotland which manufactured the company’s glucose testing strips. During his 21-month tenure, he spearheaded efforts to increase the operation’s efficiency, building the capacity to cost-effectively produce over 1 billion test strips annually. He was also responsible for the transfer of the manufacturing of the company’s meter products to China.

Prior to Inverness, John was the Vice President of Operations for Bionostics Inc., a medical reagents and controls company, and the Vice President of Manufacturing for Nova Biomedical, a medical instrumentation company. John is also the founder of Medical Devices, Inc., an engineering consulting company specializing in the offshore contract manufacturing of high volume consumer medical devices. He holds a B.S. in Biomedical Engineering from Boston University.

K. Thomas Bailey

Director

Tom Bailey joined the Company as Chief Financial Officer in March 2014. Prior to joining Agamatrix as CFO, Mr. Bailey served as President and CEO for Angiotech Pharmaceuticals Inc. until the fall of 2013, at which time he transitioned to Angiotech’s board. As CEO of Angiotech, Mr. Bailey led the company through a successful operational restructuring, and concluded the sale of one of Angiotech’s two medical device products businesses, generating significant returns for Angiotech’s shareholders. Prior to being named Angiotech’s CEO in the fall of 2011, Mr. Bailey served for six years as Angiotech’s CFO, and for two years as its Vice President, Business Development. Prior to Angiotech, Mr Bailey worked as an investment banker in the life sciences practice group at Credit Suisse First Boston and Donaldson, Lufkin & Jenrette.

Mr. Bailey currently serves as a member of the Board of Directors for Angiotech Pharmaceuticals, Inc. and LifeCare Management Services. He is a graduate of Harvard University, and also received his MBA from Harvard Business School.

Carlos A. Ferrer

Director

Carlos A. Ferrer is a founding member of Ferrer Freeman & Company, LLC.Prior to creating FFC, Mr. Ferrer was a Managing Director at Credit Suisse First Boston. From 1982 through 1995, he developed and served as Head of CSFB’s Global Health Care Investment Banking Group. He is Vice Chairman of the Board of Trustees of the Cancer Research Institute, and a member of the Board of Directors of Ardent Health Services, LLC, GeneraMedix Pharmaceuticals Inc., OrthoRx, Inc., Preferred Care Partners Holding, Corp., and Viant Holdings, Inc. He graduated from Princeton University.

Dr. Paul Kelly

Director

Dr. Paul Kelly is Managing Director of Australian venture capital firm, OneVentures, and has held numerous executive positions in the biotechnology industry. Paul is currently Chair of Vaxxas Pty Ltd, Hatchtech Pty Ltd and non-executive director of Charm Health Pty Ltd.

Paul co-founded NASDAQ listed Gemini Genomics plc, which was acquired by Sequenom (Nasdaq: SQNM) in 2001 and led the restructuring of another listed US company, Orchid Cellmark (Nasdaq: ORCH), generating substantial returns and exits for investors. Dr Kelly led the seed financing of Agamatrix in 2002 and co-founded Mears Technologies Inc, a Boston based engineered materials company focused on the development and commercialization of products based on its proprietary electronic materials platform. In addition he has assisted and led a number of early-stage and mid stage companies achieve business results in order to attract funding and transform their ideas, technologies and products into sustainable successful businesses.

Walter Winshall

Director

Walt is a principal in Collaborative Seed and Growth Partners, LLC, an investment firm specializing in the commercialization of early-stage technology. Previously, he was a co-founder and Chairman of SilverPlatter International, NV, a company providing information services for libraries, which was acquired by the Dutch publishing company Wolters Kluwer in 2001. He graduated from MIT in electrical engineering and from the Harvard Law School. At AgaMatrix, Walt provides guidance in corporate development strategy.